Using New TB Medicines and Regimens

The complete course outline is listed below. Use this tab to select learning modules/units and track your progress. Please login to see the course outline.

Module 1 Introduction & Current Guidelines
Module 1: This module contains foundational information about bedaquiline, delamanid, other new TB medicines and the short course regimen. There is also information about general management of MDR and XDR TB based on WHO guidelines.
Unit 1 Module 1: Pre-Test
Unit 2 Module 1: Current WHO Guidelines for MDR & XDR–TB
Unit 3 Module 1: New Drugs for MDR & XDR-TB-Bedaquiline (Bdq)
Unit 4 Module 1: New Drugs for MDR & XDR-TB-Delamanid (Dlm)
Unit 5 Module 1: Other Drug Treatments for MDR & XDR-TB
Unit 6 Module 1: 9 to 12 Month Treatment Regimens
Powered By WP Courseware

Module 2 The WHO Approach for New TB Drug Introduction
Module 2: This module discusses WHO recommendations for introduction of new TB medicines under programmatic conditions including five key conditions to be met in order to use the medicines. This module may be of particular interest to decision makers within the National TB Control Programs and the Ministry of Health when planning to adopt new medicines and regimens.
Unit 1 Module 2: The WHO Approach for New TB Drug Introduction
Unit 2 Module 2: The WHO Approach: Policy Guidelines on New TB Drugs
Powered By WP Courseware

Module 3 New and Repurposed TB Medicines
Module 3: This module discusses the regrouping of TB medicines based on the WHO 2016 MDR TB Guidelines. This is used to inform TB treatment regimen design based on patient history, drug use and other factors. Information in this module may be of particular interest to healthcare workers including physicians, nurses and pharmacists.
Unit 1 Module 3: WHO Suggested Grouping of Anti-TB Drugs
Powered By WP Courseware

Module 4 Clinical Considerations for Bedaquiline (Bdq) and Delamanid (Dlm)
Module 4: This module provides a more in depth review of how to use new TB medicines in a clinical setting. Information in this module may be of particular interest to healthcare workers including physicians, nurses and pharmacists.
Unit 1 Module 4: Clinical Issues Involved in the Introduction of Bdq & Dlm
Unit 2 Module 4: Additional Considerations for the Use of Bedaquiline (Bdq) in Special Populations
Unit 3 Module 4: Monitoring Patients on Bedaquiline (Bdq)
Unit 4 Module 4: Role of Clinical Review Committees
Unit 5 Module 4: Additional Considerations for the Use of Delamanid (Dlm)
Unit 6 Module 4: Practice Case Studies
Powered By WP Courseware

Module 5 Optimal Monitoring and Management of Adverse Events in Patients with Drug-Resistant TB
Module 5: This module is a comprehensive review of the most frequent adverse events in patients using all TB medicines and suggestions for management. The information here can be used during routine patient care and in documentation of adverse events. It may be of particular interest to healthcare workers including physicians, nurses and pharmacists.
Unit 1 Module 5: Adverse Events in the Treatment of DR-TB
Unit 2 Module 5: Liver Function Abnormalities
Unit 3 Module 5: Renal Failure
Unit 4 Module 5: Nausea, Vomiting & Diarrhea
Unit 5 Module 5: Psychosis & Depression
Unit 6 Module 5: Seizures & Peripheral Neuropathy
Unit 7 Module 5: QTc Prolongation
Unit 8 Module 5: Hearing & Vision Loss
Unit 9 Module 5: Hematological Abnormalities
Unit 10 Module 5: Pancreatitis
Unit 11 Module 5: Hypothyroidism
Unit 12 Module 5: Arthralgia
Unit 13 Module 5: Skin Color Changes & Rash
Unit 14 Module 5: Unclassified Serious Adverse Events
Unit 15 Module 5: Additional Overarching Cases to Assess
Powered By WP Courseware

Module 6 Ethical Considerations for the Use of Bedaquiline (Bdq) & Delamanid (Dlm)
Module 6: This module discusses the ethical issues and requirements in using new TB medicines under programmatic conditions. Healthcare workers AND decision makers within the National TB Control Programs and the Ministry of Health are recommended to review this information. The information here should be used when planning to adopt new medicines and regimens as well as when discussing with patients before starting new medicines.
Unit 1 Module 6: Ethical Considerations for the Use of Bdq & Dlm
Powered By WP Courseware

Module 7 Pharmacovigilance (PV) & New TB Medicines
Module 7: This module focuses on adverse event recording and reporting as an important part of patient care. Healthcare workers should review this module as they will be involved in recording adverse event information on all TB medicines and regimens. This important information will also be useful in clinical decision making and monitoring patient safety, risk management and quantifying drug needs. This module may also be of particular interest to decision makers within the National TB Control Programs and the National Drug Regulatory Authorities.
Unit 1 Module 7: Pharmacovigilance Definition, Key Terms, Importance & Framework
Unit 2 Module 7: Active PV in the Field
Unit 3 Module 7: Patient Chart Recording
Powered By WP Courseware

Module 8 Recording and Reporting – Generating Evidence for Scale-Up
Module 8: This module may be of particular interest to decision makers within the National TB Control Programs and the Ministry of Health. The information here should be used when planning to adopt new medicines and regimens.
Unit 1 Module 8: Generating Evidence for Scale-Up
Unit 2 Module 8: Post-Test
Powered By WP Courseware